
by Fatemeh Rahmatabadi: This week’s journal club focuses on a study from Scientific Reports (2019) exploring the the concomitant inhibition of MEK-ERK1/2 and FLT3 as a strategy to overcome drug-resistance in acute myeloid leukemia (AML).

by Fatemeh Rahmatabadi Venetoclax resistance in acute lymphoblastic leukemia is characterized by increased mitochondrial activity and can be overcome by co-targeting oxidative phosphorylation. Enzenmüller et al. explore why B-cell precursor acute lymphoblastic leukemia (BCP-ALL) cells sometimes resist the BCL-2 inhibitor…